Marc André Ceusters

This inventor holds 6 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignee: Janssen Pharmaceutica Nv. Active years: 2007-2024.

USPTO Granted Patents = 6 (Patent Applications = 3)

% Patents Active = 83.3

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 7.2

ph-index = 2

Forward Citations = 12(Granted Patents)

Company Filing History:

6 out of 2,099

Janssen Pharmaceutica Nv

patents

Years Active: 2007-2024

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12048696 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2024-07-30),

2. 11369606 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2022-06-28),

3. 11103506 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2021-08-31),

4. 10537573 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2020-01-21),

5. 9708315 - 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors (2017-07-18),

6. 7208503 - Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives (2007-04-24),

Title: Marc André Ceusters: Innovator in Metabotropic Glutamatergic Receptor Research

Introduction

Marc André Ceusters is a notable inventor based in Diest, Belgium. He has made significant contributions to the field of pharmacology, particularly in the area of metabotropic glutamatergic receptors. With a total of 6 patents to his name, Ceusters is recognized for his innovative approaches to drug development.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use." This invention focuses on combinations that include a positive allosteric modulator (PAM) of metabotropic glutamatergic receptor subtype 2 (mGluR2) or a pharmaceutically acceptable salt or solvate thereof. It also encompasses orthosteric agonists of mGluR2 and their applications in therapeutic settings.

Career Highlights

Marc André Ceusters is currently associated with Janssen Pharmaceutica NV, a leading pharmaceutical company. His work at Janssen has allowed him to explore innovative solutions in drug development, particularly in the realm of neurological disorders. His research has the potential to impact the treatment of various conditions by targeting specific receptor subtypes.

Collaborations

Ceusters has collaborated with esteemed colleagues such as José Maria Cid-Núñez and Andrés Avelino Trabanco-Suárez. These collaborations have fostered a dynamic research environment, enhancing the development of novel therapeutic strategies.

Conclusion

Marc André Ceusters stands out as a prominent inventor in the field of pharmacology, with a focus on metabotropic glutamatergic receptors. His contributions through patents and collaborations continue to advance the understanding and treatment of neurological disorders.